Trial Profile
Multicenter phase II study of docetaxel/cisplatin/bevacizumab combination therapy in patients with advanced non-squamous non-small cell lung cancer (TORG1016)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Sep 2018
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin (Primary) ; Docetaxel (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 02 Mar 2018 Status changed from active, no longer recruiting to completed, as per the results published in the BMC Cancer
- 24 Nov 2015 New trial record